Table 2. CIGB-300 tumour uptake.
| Parameter | Group I (35 mg), N=6a | Group II (70 mg), N=7 | P (95% CI) |
|---|---|---|---|
| Maximum % ID | 46.1±25.7 (10.8–77.7) | 44.7±18.4 (14.2–69.6) | 0.32 (−14.1; 33.5) |
| Maximum uptake (mg CIGB-300) | 16.1±8.9 (3.8–27.2) | 31.3±12.9 (9.9–48.7) | 0.01 (6.3; 27.8) |
| Maximum uptake (mg CIGB-300 per g tumour) | 0.7±0.6 (0.04–1.9) | 1.1±0.8 (0.4–2.7)b | 0.24 (−0.8; 1.2) |
| AUC24 (mg h) | 132±72.2 (45.3–235) | 385±167 (90.3–646) | 0.00 (182; 434) |
| Biological half-life (h) | 3.9±0.9 (2.6–5.5) | 6.2±1.9 (3.5–10.1) | 0.00 (1.6; 4.4) |
Abbreviations: AUC=area under curve; CI=confidence interval for the differences; ID=injected drug.
Data are reported as mean±s.d. (range).
P: probability that the difference was >0.
a
One patient did not receive the CIGB-300 because of suboptimal radiolabelling.
b
N=6 since MRI data were insufficient to estimate tumour mass in one patient.